Growth Hormone Treatment in Children Born Small for Gestational Age: Assessment of Satisfaction
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This trial is conducted in Europe. The aim of this trial is to assess satisfaction with growth hormone treatment in children of both sexes born small for gestational age and who are receiving growth hormone treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
6 Years to 15 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Children treated for 3 years with Maxomat® because of small for gestational age
Postnatal growth failure by the age of 3 years or more
No associated growth hormone deficiency
Height growth velocity greater than 2 cm/yr over the 12 month period preceding the inclusion
Bone age no more than 13 years for girls and no more than 15 years for boys
Known, evolving tumour
Hypertension not controlled on maximum therapy
Benign intracranial hypertension
Known glucose intolerance or known diabetes mellitus
Acute or active chronic hepatitis
Chronic renal failure
Chromosomal and/or genetic syndromes (other than Silver-Russell syndrome) or abnormality